Printer Friendly

DEVELOPER OF HUMAN ANTIBODIES JOINS PROTEIN DESIGN LABS

 MOUNTAIN VIEW, Calif., May 12 /PRNewswire/ -- Protein Design Labs, Inc. (NASDAQ: PDLI) ("PDL") today announced that Lars Ostberg, M.D., will join the company as a senior scientist. Dr. Ostberg led the development of human anti-viral antibodies PDL recently acquired from Sandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp.
 Dr. Ostberg has been director of monoclonal antibody research at Sandoz since 1984. In that capacity, he was responsible for the creation of proprietary technology for producing stable human antibodies.
 Last month, PDL acquired this technology as well as four human anti- viral antibodies made with this technology. Human antibodies against cytomegalovirus (CMV) and the hepatitis B virus have completed Phase I/II clinical trials. PDL intends to begin Phase II/III clinical trials next year with the human anti-CMV antibody for CMV retinitis in AIDS patients and the human anti-hepatitis B antibody for liver transplant patients with end-stage liver disease from chronic B infection.
 "Dr. Ostberg will provide important scientific and development support as PDL takes the promising human anti-viral antibodies he developed through clinical trials," said Cary L. Queen, Ph.D., vice president, research of PDL. "He will also participate in integrating the technology acquired from Sandoz with genetic methods for making human antibodies that are under development at PDL in an effort to produce human antibodies against a wider variety of medically important targets." Dr. Ostberg's appointment is effective next month.
 The Sandoz-developed "trioma" technology uses a human-mouse hybridoma as a fusion partner for human B cells that have been isolated from the blood or spleen and have high binding affinity for the target virus. Trioma cells have unusually stability and can be scaled up for commercial production.
 Dr. Ostberg is the second senior researcher from Sandoz to join PDL to continue work on these human antibodies. Paul I. Nadler, M.D., formerly vice president, medical research at Sandoz, became vice president, medical and regulatory affairs at PDL in February.
 Protein Design Labs, founded in 1986, is engaged in the development of next-generation antibodies and other novel proteins to treat various conditions, including viral infections, autoimmune and inflammatory diseases and cancer.
 The company has two core proprietary antibody technologies. In addition to human antibodies for viral infections, PDL uses computer modeling techniques to combine the binding site of a mouse antibody with a large of a human antibody. The resulting SMART(TM) Antibodies, which are more than 90 percent human, retain high binding affinity for the target antigens and will, PDL believes, substantially reduce or avoid the human anti-mouse monoclonal antibody (HAMA) response that has limited the use of mouse monoclonal antibodies as human therapeutics. Two SMART Antibodies are in clinical trials.
 SMART Antibodies have potential as therapeutic agents against human proteins and other targets for which it is generally not possible to obtain human antibodies. SMART Antibodies also may be used for anti- viral therapy.
 -0- 5/12/93
 /CONTACT: Peter Dworkin, director of corporate communications of Protein Design Labs, 415-903-3721/
 (PDLI)


CO: Protein Design Labs, Inc. ST: California IN: MTC SU: PER

TM -- NY009 -- 7332 05/12/93 07:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1993
Words:514
Previous Article:DEKALB ENERGY REPORTS EARNINGS OF $6.7 MILLION IN FIRST QUARTER; CITES STRONG NATURAL GAS MARKET AND ONE-TIME TAX BENEFIT
Next Article:DIGITAL BIOMETRICS ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
BRENT LARSEN NAMED DIRECTOR, PROCESS DEVELOPMENT FOR PROTEIN DESIGN LABS
PROTEIN DESIGN LABS HIRES VETERAN BUSINESS JOURNALIST FOR COMMUNICATIONS POST
PROTEIN DESIGN LABS APPOINTS JAMES CORNETT DIRECTOR, BUSINESS DEVELOPMENT
PHARMACEUTICAL EXECUTIVE MAX LINK ELECTED DIRECTOR OF PROTEIN DESIGN LABS
Protein Design Labs Grants Second License Under Antibody Humanization Patents to IDEC Pharmaceuticals
Protein Design Labs Announces Agreement With Fujisawa.
Protein Design Labs Announces Multiple Humanization Patent License Agreements With Chugai.
Protein Design Labs to Humanize Antibody for Lilly.
Protein Design grants license to Celltech under patent.
Abbott and Protein Design Labs Announce Broad, Long-Term Collaboration for Humanized Therapeutic Antibodies.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters